Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Центр психического здоровья Минздрава Азербайджанской республики. AZ1154, Азербайджан, Баку, Наримановский р-н, ул. И.Хидаятзаде №4 ismayilova.d@gmail.com
Список исп. литературыСкрыть список 1. Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med 2014; 44 (14): 3007–16. DOI: 0.1017/S0033291714000610 2. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012; 42 (10): 2145–55. DOI: 10.1017/S0033291712000220 3. Wunderink L, Nienhuis FJ, Sytema S et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68 (5): 654–61. 4. Wunderink L, Nieboer RM, Wiersma D et al. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry 2013. [Epub ahead of print] PMID: 23824214. 5. Morrison AP, Hutton P, Wardle M et al. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychol Med 2012; 42 (5): 1049–56. DOI: 10.1017/S0033291711001899 6. Landolt K, Rössler W, Ajdacic-Gross V et al; EUFEST Study Group. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). 7. Lieberman JA, Tollefson GD, Charles C et al; HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62 (4): 361–70. 8. Ho BC, Andreasen NC, Ziebell S et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68 (2): 128–37. DOI: 10.1001/archgenpsychiatry.2010.199 9. Veijola J, Guo JY, Moilanen JS et al. Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One 2014; 9 (7): e101689. DOI: 10.1371/journal.pone.0101689 10. Jääskeläinen E, Juola P, Hirvonen N et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39 (6): 1296–306. DOI: 10.1093/schbul/sbs130 11. Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41 (3): 656–63. DOI: 10.1093/schbul/sbu164 12. Ran MS, Weng X, Chan CL et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry 2015; 207 (6): 495–500. DOI: 10.1192/bjp.bp.114.157685 13. Leucht S, Tardy M, Komossa K et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379 (9831): 2063–71. DOI: 10.1016/S0140-6736(12)60239-6 14. Leucht S, Hierl S, Kissling W et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200 (2): 97–106. DOI: 10.1192/bjp.bp.111.096594 15. Andreasen NC, Liu D, Ziebell S et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170 (6): 609–15. DOI: 10.1176/appi.ajp.2013.12050674 16. Ascher-Svanum H, Peng X, Faries D et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry 2009; 9: 46. DOI: 10.1186/1471-244X-9-46 17. Alvarez-Jimenez M, O'Donoghue B, Thompson A et al. Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs 2016; 30 (5): 357–68. DOI: 10.1007/s40263-016-0331-x 18. Gaebel W, Riesbeck M, Wölwer W et al; German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2011; 72 (2): 205–18. DOI: 10.4088/JCP. 09m05459yel 19. Schizophr Res 2016; 172 (1–3): 145–51. DOI: 10.1016/j.schres. 2016.01.046